Relationship Between the Clinical Pharmacist & Antibiotic Use by Using the Electronic Program

Completed

• Conditions: Electronic Medical Record; Clinical Pharmacists
• Interventions: Other: NO intervention

• Registration Number: NCT05002647
• Lead Sponsor: Alexandria University

Brief Summary

A retrospective cohort study to explore the association between clinical pharmacists' interventions and antibiotic consumption through the use of the medical electronic reports and to identify mortality and cost savings in hospital infectious disease.

Detailed Description

The role of clinical pharmacist includes :

1. a check of suitable selection and dosing of antimicrobials according to the diagnosis, type of infection, antimicrobial cultures as possible, comorbidities of patients (renal or hepatic function, etc), adverse effect, and drug interaction with other drugs.

2. Documentation of the clinical intervention, cost-saving, adverse effect,, antimicrobial culture and antimicrobial consumption on the electronic program (CPC "clinical patient care").

3. The clinical pharmacist inspector reviews the data recorded on CPC.

Study Timeline

• Status Verified: 2021-08
• Study First Submitted: 2021-08-07
• Study First Submitted QC: 2021-08-07
• Study First Posted: 2021-08-12
• Study Start: 2021-09-15
• Primary Completion: 2022-01-01
• Study Completion: 2022-03-10
• Last Update Submitted: 2024-12-23
• Last Update Posted: 2024-12-27

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 2601

Inclusion Criteria

• All inpatient with infectious disease (disorders caused by organisms as (bacteria, viruses, fungi, or parasites).

Exclusion Criteria

• Any other cause of hospital admission other than infectious disease.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Non-exposure group B	NO intervention	Data from a medical record of the hospital with clinical pharmacy, but the department did not cover by the clinical pharmacy
exposure group	NO intervention	Data from electronic clinical pharmacist records of two infectious disease hospitals
Non-exposure group A	NO intervention	Data from medical records of the hospital with no clinical pharmacy.

Primary Outcome Measures

Name	Time	Method
Length of therapy(LOT)	2 years	The number of days a patient takes an antibacterial drug, regardless of the number of different medications
Antimicrobial consumption	2 years	consumption of antimicrobials (defined daily doses / 100 patient-days)
Days of therapy (DOT)	2 years	Number of days of each antimicrobial received for therapy

Secondary Outcome Measures

Name	Time	Method
Antimicrobial resistance	2 years	resistance defined as resistance to at least one antimicrobial from the panel for all organisms, and for a subset of organisms belonging to the ESKAPE group (Enterococcus faecium, S. aureus, Klebsiella pneumonia, Acinetobacter baumannii, Pseudomonas aeruginosa , and Enterobacter spp.
The incidence of adverse reaction of antimicrobial	2 years	An unexpected medical problem that happens during treatment with antimicrobial.
Mortality rate	2 years	in-hospital mortality rate (%)
cost savings	2 years	(initial treatment cost × days before intervention) - (cost after intervention × days with this treatment),

Trial Locations

Locations (1)

Ministers of health; 🇪🇬 Alexandria, Egypt